Navigation Links
Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine

OSS, The Netherlands, June 11, 2007 /PRNewswire/ -- Sugammadex - the novel selective relaxant binding agent (SRBA) being developed by Organon, the human healthcare business unit of Akzo Nobel - demonstrated in a Phase III pivotal trial a 9-12 times faster reversal of neuromuscular blockade as compared to neostigmine, without evidence of post operative residual curarization (PORC) or re-occurrence of muscle relaxation.(1),(2) The results of this pivotal Aurora trial were presented today at the 14th annual Euroanaesthesia 2007 congress in Munich, Germany.

The Aurora trial compared the efficacy of sugammadex and neostigmine for the reversal of shallow neuromuscular blockade induced by single or multiple doses of either rocuronium (Esmeron(R)/Zemuron(R)) or vecuronium (Norcuron(R)).

"Sugammadex has shown a rapid and complete reversal in this pivotal trial without evidence of PORC or re-occurrence of neuromuscular blockade. Effective reversal is critically important to ensure that patients recover quickly and completely, without the risk of breathing difficulties," commented one of the lead investigators involved in the Aurora trial, Professor M. Blobner from the Klinik fur Anasthesiologie der Technischen Universitat Munchen, Germany.

Reversal agents are used during general anesthesia to reverse the effects of muscle relaxants, also called neuromuscular blocking agents (NMBAs). Reversal of neuromuscular blockade is used to reduce the risk of PORC or re-occurrence of muscle relaxation.

Phase III Trial Overview

The international, randomised, multicenter, parallel-group Aurora trial was conducted at 13 European centers and enrolled 198 patients. In the trial sugammadex was administered at reappearance of T2 and achieved significantly faster recovery of the T4/T1 ratio to 0.9 compared with neostigmine. Median time to recovery was 1.4 minutes (0.9-5.4; p<0.0001) for sugammadex versus 17
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
2. Organons Asenapine Effective in a Phase III Study for the Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA Meeting
3. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
4. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
5. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
6. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
7. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
8. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
9. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
10. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Post Your Comments:
(Date:7/23/2008)...nds Some Areas of the Body Have Greater Concentrat... 23 /PRNewswire-USNewswire/ -- Fat removed,from th...n was found to be,an excellent source of stem cell... areas of the body, reports a Brazilian-based stud...), the official medical journal of the,American So...
(Date:7/22/2008)...tralia, July 22 /- Followin... the Board of Progen,Pharmaceuticals Limited (ASX:...scontinued the PI-88 phase 3 study in liver cancer...lop its existing portfolio of compounds and,the co...pounds and,opportunities through Merger & Acquisit...
(Date:7/22/2008)...g to Discuss Development Plan Completed Successful...l/ -- Amarin Corporation,plc (NASDAQ: AMRN ) toda...icials at the U.S. Food and Drug Administration (F...01 for the treatment of,hypertriglyceridemia. Foll... to Phase 3 with AMR101 in hypertriglyceridemia., ...
(Date:7/22/2008)...llan Will Stress the Importance to Patients of Pas...al Pathway, RICHMOND, Va., July 22 /PRNewswire-Fi...per of follow-on biologics and biopharmaceuticals,...f Insmed, will present at a,Congressional briefing...cant need for establishing an approval pathway for...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast 10496 1Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast 10496 2Markets of biodiversity and equity in trade 3A An illusion 3F 2058 1Markets of biodiversity and equity in trade 3A An illusion 3F 2058 2Markets of biodiversity and equity in trade 3A An illusion 3F 2058 3American Journal of Disaster Medicine Accepted for Inclusion into The National Library of Medicines MEDLINE Database and may now be Accessed Through t 10495 1American Journal of Disaster Medicine Accepted for Inclusion into The National Library of Medicines MEDLINE Database and may now be Accessed Through t 10495 2Life 3AWIRE 28TM 29 to Provide Action Healthcare Management with Innovative Mobile Health Management Solution for Patients with Chronic Conditions 10492 1Life 3AWIRE 28TM 29 to Provide Action Healthcare Management with Innovative Mobile Health Management Solution for Patients with Chronic Conditions 10492 2
... /PRNewswire-FirstCall/ -- Iomai,Corporation today...Phase 1 trial of its patch-based needle-free influ...onference call and live,webcast will be held at 8:...ts. , Conference Call Details , To access the live... Eastern Time via phone, please dial 888-396-2356 ...
... 2007 - HepaLife Technologies, Inc.,(OTCBB:HPLF) (...entific presentation of its cell based PBS-1 techn...t the "Options for the,Control of Influenza VI Con... Canada., Entitled "High titer growth of human and...embryo cell line without the need for,exogenous pr...
Other Medicine Technology:Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 2HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 3HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 4HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 5
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
... cancer often results in radiation-induced damage ..., targeted over-expression of heat shock protein 2...by Lee et al., "Radioprotective effect of HSP25 on...ished in the November issue of The American Journa...
...ilities, Health Minister Anbumani Ramadoss has bla...//, which has so far taken toll of over 130 lives ...par for the CNN-IBN programme Devil's Advocate to ...Even though I don't want to shy away from my respo...
... scientists that plays a key role in advancing inf...chers// who feel this might be the breakthrough lo...ntestinal diseases such as Crohn’s disease and ulc...een implicated with many chronic illnesses associa...
...omen who thrive on a diet which is rich in helping...he like //which is highly refined energy food gain...women who conscientiously take a diet rich in fibe...ned food is easily broken down to simple sugar, gl...
Other Medicine News:Health News:Radioprotective effect of Heat Shock Proteins 2Health News:Ramadoss Blames State Governments for High Dengue Toll 2Health News:Ramadoss Blames State Governments for High Dengue Toll 3
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: